Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2026, Quick Ratio deteriorated to 0.09 below Dr Reddy S Laboratories Limited's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 428 other companies have achieved higher Quick Ratio than Dr Reddy S Laboratories Limited in fourth quarter 2026. While Quick Ratio total ranking has improved so far during the Q4 2026 to 3909, from total ranking in the third quarter 2026 at 4783.

Explain Quick Ratio?
How much Cash & cash equivalents RDY�s has?
What are RDY�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/RDY/financial-strength

https://api.csimarket.com/api/v1/companies/RDY/fundamentals

https://api.csimarket.com/api/v1/companies/RDY/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

RDY Quick Ratio	(Mar 31 2026) Q4	0 Q3	0 Q2	0 Q1	(Mar 31 2025) Q4
Y / Y Current Liabilities Change	17.03 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-4.65 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.09	Subscribe	Subscribe	Subscribe	Subscribe
RDY's Total Ranking	# 3909	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-3.51 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-4.65 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio fourth quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 429
Healthcare Sector	# 860
Overall Market	# 3839

Quick Ratio Statistics
High	Average	Low
0.36	0.13	0.06
0		0

Financial Statements
Dr Reddy S Laboratories Limited's Current Liabilities	$ 1,787 Millions	Visit RDY's Balance sheet
Dr Reddy S Laboratories Limited's Cash & cash equivalent	$ 164 Millions	Visit RDY's Balance sheet
Source of RDY's Sales		Visit RDY's Sales by Geography

Cumulative Dr Reddy S Laboratories Limited's Quick Ratio

RDY's Quick Ratio for the trailling 12 Months

RDY Quick Ratio	(Mar 31 2026) 12 Months	0 12 Months	0 12 Months	0 12 Months	(Mar 31 2025) 12 Months
Y / Y Current Liabilities TTM Growth	13.47 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	10.48 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	0.09	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 4122	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	3.74 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-1.19 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to RDY Financial Strength Comparisons >> Go to Compare RDY Quick Ratio to its Competitors

On the trailing twelve months basis Due to decrease in Current Liabilities in the Q4 2026 to $1,787.00 millions, cumulative Quick Ratio decreased to 0.09 below the Dr Reddy S Laboratories Limited average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 444 other companies have achieved higher Quick Ratio than Dr Reddy S Laboratories Limited. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2026 from 3522 to 4122.

Explain Quick Ratio?
How much Cash & cash equivalents RDY�s has?
What are RDY�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 445
Healthcare Sector	# 913
Within the Market	# 4122

trailing twelve months Quick Ratio Statistics
High	Average	Low
0.18	0.09	0.03
(Mar 31 2021)		(Mar 31 2020)

Companies with similar Quick Ratio in the quarter ending Mar 31 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Mar 31 2026 MRQ Cash & cash equivalent	Mar 31 2026 MRQ Current Liabilities
Akari Therapeutics Plc	0.25	$ 2.768 Millions	$ 10.975 Millions
Abbvie Inc	0.22	$ 9,391.000 Millions	$ 42,100.000 Millions
Merck and Co Inc	0.21	$ 5,702.000 Millions	$ 26,945.000 Millions
Indivior Pharmaceuticals Inc	0.21	$ 175.000 Millions	$ 850.000 Millions
Xencor Inc	0.19	$ 14.170 Millions	$ 73.457 Millions
International Stem Cell Corporation	0.18	$ 0.933 Millions	$ 5.049 Millions
Jaguar Health Inc	0.18	$ 7.278 Millions	$ 40.686 Millions
Lunai Bioworks Inc	0.16	$ 3.155 Millions	$ 19.283 Millions
Shuttle Pharmaceuticals Holdings Inc	0.13	$ 1.090 Millions	$ 8.306 Millions
Propanc Biopharma Inc	0.13	$ 0.444 Millions	$ 3.476 Millions
Summit Therapeutics Inc	0.11	$ 8.238 Millions	$ 76.193 Millions
Polomar Health Services, Inc.	0.10	$ 0.097 Millions	$ 0.924 Millions
Bioxytran Inc	0.09	$ 0.463 Millions	$ 5.010 Millions
Dr Reddy s Laboratories Limited	0.09	$ 164.000 Millions	$ 1,787.000 Millions
Citius Pharmaceuticals Inc	0.08	$ 4.590 Millions	$ 55.016 Millions
Igc Pharma Inc	0.08	$ 0.235 Millions	$ 2.873 Millions
Cv Sciences Inc	0.08	$ 0.309 Millions	$ 3.799 Millions
Hcw Biologics Inc	0.06	$ 1.229 Millions	$ 19.959 Millions
Os Therapies Incorporated	0.05	$ 0.918 Millions	$ 18.331 Millions
Citius Oncology Inc	0.04	$ 2.633 Millions	$ 58.812 Millions
Abvc Biopharma Inc	0.04	$ 0.203 Millions	$ 5.393 Millions
IMPACT BIOMEDICAL INC.	0.03	$ 0.020 Millions	$ 0.584 Millions
Provectus Biopharmaceuticals Inc	0.03	$ 0.224 Millions	$ 7.242 Millions
Evofem Biosciences Inc	0.03	$ 2.379 Millions	$ 78.752 Millions
Gridai Technologies Corp	0.02	$ 0.386 Millions	$ 16.232 Millions
Aditxt Inc	0.02	$ 0.269 Millions	$ 11.452 Millions
China Pharma Holdings Inc	0.02	$ 0.168 Millions	$ 7.268 Millions
Northwest Biotherapeutics Inc	0.02	$ 1.786 Millions	$ 82.973 Millions
Lakewood-Amedex Biotherapeutics Inc.	0.02	$ 0.012 Millions	$ 0.548 Millions
Zyversa Therapeutics Inc	0.02	$ 0.303 Millions	$ 14.739 Millions

Date modified: 2026-07-07T13:23:39+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.